Navigation Links
ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing
Date:8/7/2008

Positive Results to Date Drive Decision to Expand its Proprietary

Therapeutic Pipeline

ZURICH, Switzerland, Aug. 7 /PRNewswire/ -- ESBATech AG, a leading developer of antibody fragment therapeutics, today announced that the company has raised an additional CHF 23M (USD 22M, EUR 14M) in an extended Series B venture round to expand its development pipeline. A global syndicate of current investors participated in this round including SV Life Sciences, Clarus Ventures, HBM BioVentures, HBM BioCapital, Novartis Bioventures, BioMedinvest and VI Partners.

This funding builds on the company's CHF 50M (USD 49M, EUR 31M) Series B round, which closed in August 2006 and has enabled the company to move its lead molecule, ESBA105, into clinical trials. ESBA105 is a single-chain antibody fragment directed against TNF-alpha and is developed in ophthalmic and additional inflammatory indications.

Dominik Escher, Ph.D., Chief Executive Officer of ESBATech AG, commented, "We are delighted to announce the expansion of our proprietary pipeline with this additional financing. This includes building broad franchises in ophthalmology, rheumatology and respiratory diseases for ESBA105 and additional antibody fragments. Since the announcement of the Series B financing in August 2006, ESBATech has made significant progress in R&D, including the demonstration in animal models that high concentrations of ESBA105 can be achieved in all segments of the eye with topical delivery via eye drops. Furthermore, we have advanced our anti-VEGF program to selection of a development candidate, ESBA903, a single-chain antibody that shows very high potency, stability and solubility, and will be developed for ophthalmic indications. Just like ESBA105, this antibody fragment will be delivered via eye drops and thus represents a true alternative to the current intra-vitreal injections of marketed anti-VEGF inhibitors."

Martin Gertsch, Chief Financial Officer of ESBATech AG, commented, "To date, with this additional capital increase, the company has raised over CHF 88M (USD 86M, EUR 54M) for the development of its antibody fragment platform as well for the advancement of product candidates into the clinic. With one ongoing Phase I clinical study, an additional clinical trial pending commencement, and additional programs in and nearing formal preclinical development, this is a time of growth for ESBATech. We are building the company to be the leader in antibody fragment therapeutics."

Graham Boulnois, Ph.D., Partner with SV Life Sciences, commented, "We are delighted with the progress of ESBATech to date. The company's human antibody fragment platform has delivered a growing pipeline of commercially attractive new drugs based on stable antibody fragments derived from fully human scaffolds. This is an exciting area and provides the company with high value opportunities for partnering across multiple therapeutic areas."

Michael Steinmetz, Ph.D., Managing Director of Clarus Ventures, added, "ESBATech's unique approach to antibody fragments derived from fully human scaffolds position them well in this highly exciting growth market. We look forward to further clinical development of the company's product pipeline and additional value generation."

About ESBATech AG

ESBATech AG is a Zurich, Switzerland-based, privately held drug discovery and development company focused on advancing antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery.

In the first half of 2008, the company initiated a Phase I clinical study of ESBA105 in ophthalmic indications. The study is being conducted as a single and repeated dose escalation study in Switzerland and is designed to evaluate the safety, tolerability and pharmacokinetic profile of ESBA105 when delivered topically via eye drops in healthy volunteers. The company expects to initiate an additional clinical study in the coming months.

Current venture investors include SV Life Sciences, Clarus Ventures, HBM BioVentures, HBM BioCapital, Novartis Bioventures, BioMedinvest and VI Partners. For more information about ESBATech, please visit, http://www.esbatech.com.


'/>"/>
SOURCE ESBATech AG
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ESBATechs Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
2. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
3. Light Sciences Oncology Raises $40.1 Million in Series C Financing
4. Romark Laboratories Raises $18 Million in Institutional Financing
5. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
6. EntreMed Raises $20 Million to Support Clinical Development Program
7. Globus Medical Raises $110 Million in Series E Financing Round
8. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
9. AlphaDetail AlphaPulse(TM): Most Practicing Physicians React Positively to FDA Panels Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications.
10. Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)
11. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... Cirujanos holandeses han puesto en marcha una ... compartir sus mejores prácticas por el mundo y tratar ... Europa, África, Asia y Estados ... combina la transmisión en vivo con mensajería instantánea y ... "Imagine un médico de Medicines sans Frontieres ...
(Date:5/24/2016)... HENDERSON, Nev. , May 24, 2016  Diana ... painfully "eats" her organs from the inside out.  This ... her completely dependent on her children and grandchildren to ... of her wheelchair, Diana,s family cannot haul the wheelchair.  ... rides in the car, and Diana is left to ...
(Date:5/24/2016)... May 24, 2016 Celsion Corporation (NASDAQ: ... company, today provided an update on its ongoing ... trial combining GEN-1, the Company,s DNA-based immunotherapy, with ... newly-diagnosed patients with advanced ovarian cancer who will ... GEN-1 is an IL-12 DNA plasmid vector formulated ...
Breaking Medicine Technology:
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, ... ... health care world, this installment is bolstered by inspiring human interest stories, courtesy ... to the developing trends and tech within the industry, from leading advocates and ...
(Date:5/27/2016)... , ... May 27, 2016 , ... ... name in the pharmaceutical, medical and food industries. Aside from its GMP accreditation, ... (SIC), providing proof of successfully certified products, services and staff. , Validation Center ...
(Date:5/26/2016)... ... May 26, 2016 , ... W.S. Badger Co. Inc ., the maker ... 2016 When Work Works Award for its use of effective workplace strategies to increase ... Works project administered by the Families and Work Institute (FWI) and the Society for ...
(Date:5/26/2016)... ... May 26, 2016 , ... Georgia State University ... specialty academic programs. , Answering to the increasing demand for curricular specializations, the ... law, and environmental and land use law. ,  , “The demand for lawyers ...
(Date:5/26/2016)... ... May 26, 2016 , ... The Woodlands at John Knox Village , ... of care for living and healing, celebrated its grand opening, today. The Woodlands at ... Home provided by Empowered Staff. , “This is an incredibly fulfilling time for John ...
Breaking Medicine News(10 mins):